Genflow Biosciences Past Earnings Performance
Past criteria checks 0/6
Genflow Biosciences's earnings have been declining at an average annual rate of -16.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 208.2% per year.
Key information
-16.9%
Earnings growth rate
184.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 208.2% |
| Return on equity | -178.4% |
| Net Margin | -256.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Genflow Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -2 | 2 | 0 |
| 31 Mar 24 | 0 | -2 | 2 | 0 |
| 31 Dec 23 | 0 | -2 | 2 | 0 |
| 30 Sep 23 | 0 | -1 | 2 | 0 |
| 30 Jun 23 | 0 | -1 | 2 | 0 |
| 31 Mar 23 | 0 | -1 | 2 | 0 |
| 31 Dec 22 | 0 | -1 | 2 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
Quality Earnings: WQ5 is currently unprofitable.
Growing Profit Margin: WQ5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WQ5 is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare WQ5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WQ5 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: WQ5 has a negative Return on Equity (-178.42%), as it is currently unprofitable.